Testing a dose of N-acetylcysteine for certain blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 study tests what dose of N-acetylcysteine (NAC) is safe and potentially helpful for people with essential thrombocythemia, polycythemia vera, or myelofibrosis. It focuses on people who still have symptoms and meet blood and health requirements so researchers can monitor side effects and symptom changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF) confirmed by 2016 WHO criteria
- Have a current MPN symptom score of 10 or higher (symptoms questionnaire)
- Not take interferon-alpha or a JAK inhibitor (like ruxolitinib or fedratinib) in the past 28 days
- Not take NAC (or NAC-containing products) in the past 28 days
- Blood tests must be adequate (no too-low kidney/liver values and platelets, hemoglobin, and neutrophils must meet thresholds)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
This trial tests an oral drug combination for people with advanced myeloproliferative neoplasms (MPNs), which are blood cancers. The treatment may help control the disease and improve symptoms.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial tests whether taking N-acetylcysteine (NAC), an antioxidant supplement, after induction chemotherapy helps your blood cells recover faster and more completely. It is designed for adults with newly diagnosed low- or intermediate-risk acute myeloid leukemia (AML) who have achieved remission.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.